Pfizer Inc.

Pfizer Inc.

PFEยทNYSE

$25.36

-0.78%
HealthcareDrug Manufacturers - General

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

At a Glance

Live Snapshot
Market Cap$144.51B
EPS1.3600
P/E Ratio18.64
Earnings Date08/04/2026
3Y-38.0%
5Y+50.0%
10Y+18.0%
3Y-75.0%
5Y-15.0%
10Y+8.0%
3Y-60.0%
5Y-19.0%
10Y-26.0%
Pfizer Inc.

Pfizer Inc. Profit Bridge

PFE ยท NYSE
Revenue62.58B
Cost of Goods Sold (18.57B)
Gross Profit44.01B
Operating Expenses (28.58B)
Operating Income15.44B
Interest Expense (2.67B)
Other Income/Expense-7.92B
Pretax Income7.52B
Income Tax (-266.00M)
Net Income7.77B
Net Income
7.77B

Profitability Analysis

Gross Margin

70.3%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

24.7%

Healthy operating margins demonstrate effective cost control and strong business fundamentals.

Net Profit Margin

12.4%

Strong net margins indicate efficient operations and favorable tax/interest management.

Effective Tax Rate

-3.5%

Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.

Profitability Insight

High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.

Pfizer Inc. Income Statement

PFE โ€ข NYSE

Pfizer Inc. Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
REVENUE
62.6B
63.6B
59.6B
100.3B
81.3B
41.7B
41.2B
53.6B
52.5B
52.8B
48.9B
49.6B
51.6B
54.7B
61B
67.1B
50B
48.3B
48.4B
48.4B
GROSS PROFIT
(18.6B)
(21.8B)
(29.2B)
(38.2B)
(34.4B)
(11.8B)
(12.6B)
(16B)
(15.8B)
(16B)
(13.2B)
(13.3B)
(14B)
(14.6B)
(17.2B)
(20.7B)
(11.6B)
(10B)
(11.7B)
(10.5B)
44B
41.8B
30.3B
62.1B
46.9B
29.9B
28.5B
37.6B
36.8B
36.9B
35.7B
36.3B
37.6B
40B
43.9B
46.3B
38.4B
38.3B
36.7B
37.9B
OPERATING INCOME
(28.6B)
(25.4B)
(25B)
(24.5B)
(26.1B)
(20.8B)
(21B)
(22.4B)
(22.4B)
(22.6B)
(22.4B)
(22.3B)
(20.7B)
(22B)
(25.5B)
(28.6B)
(22.4B)
(21.6B)
(22.8B)
(22.8B)
(13.3B)
(14.7B)
(14.5B)
(13.1B)
(12.3B)
(11.4B)
(12.7B)
(14.4B)
(14.7B)
(14.8B)
(14.7B)
(14B)
(14.2B)
(15B)
(17.5B)
(19.3B)
(14.7B)
(14.1B)
(15.2B)
(15.3B)
(12B)
(10.7B)
(10.6B)
(11.4B)
(13.8B)
(9.4B)
(8.4B)
(8B)
(7.6B)
(7.8B)
(7.7B)
(8.3B)
(6.6B)
(7B)
(8B)
(9.4B)
(7.8B)
(7.5B)
(7.6B)
(7.4B)
15.4B
16.5B
5.3B
37.5B
20.8B
9.1B
7.5B
15.3B
14.4B
14.3B
13.3B
14B
16.9B
18B
18.4B
17.7B
16B
16.6B
13.9B
15.1B
PRE-TAX INCOME
(2.7B)
(3.1B)
(2.2B)
(1.2B)
(1.3B)
(1.4B)
(1.6B)
(1.3B)
(1.3B)
(1.2B)
(1.2B)
(1.4B)
(1.4B)
(1.5B)
(1.7B)
(1.8B)
(1.2B)
(516M)
(397M)
(488M)
-2.1B
-2.5B
-585M
-987M
-1.3B
-1.4B
-1.3B
-983M
-879M
-716M
-728M
-935M
-1B
-1.1B
-1.2B
-1.4B
-487M
772M
1.1B
437M
(3.3B)
-105M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-7.9B
-8.5B
-4.2B
-2.8B
3.5B
-2B
4B
-3.4B
-2.1B
-5.9B
-4.3B
-1.8B
-1.2B
-6.8B
-6.9B
-8.5B
-5.2B
-6.9B
-4.6B
-2.1B
7.5B
8B
1.1B
34.7B
24.3B
7B
11.5B
11.9B
12.3B
8.4B
9B
12.2B
15.7B
11.2B
11.5B
9.3B
10.8B
9.7B
9.3B
13B
NET INCOME
-266M
-28M
-1.1B
(3.3B)
(1.9B)
(370M)
(618M)
(706M)
-9B
(1.1B)
(2B)
(3.1B)
(4.3B)
(2.2B)
(3.6B)
(1.1B)
(2.2B)
(1.6B)
(1B)
(2B)
7.8B
8B
2.1B
31.4B
22.1B
9.2B
16.3B
11.2B
21.3B
7.2B
7B
9.1B
11.6B
9.8B
8.7B
8.3B
8.6B
8B
8.2B
11B

SEC Filings

PFE - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
10-Q

10-Q 2026 Q1

Q1

May 05, 2026
March 29, 2026
2026
8-K

8-K 2026

N/A

May 05, 2026
May 05, 2026
2026
8-K

8-K 2026

N/A

April 27, 2026
April 23, 2026
2026
DEF 14A

DEF 14A 2026

N/A

March 12, 2026
April 23, 2026
2026
10-K

10-K 2025 FY

FY

February 26, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 03, 2026
February 03, 2026
2026
8-K

8-K 2025

N/A

December 16, 2025
December 16, 2025
2025
8-K

8-K 2025

N/A

November 21, 2025
November 18, 2025
2025
8-K

8-K 2025

N/A

November 13, 2025
November 13, 2025
2025
10-Q

10-Q 2025 Q3

Q3

November 04, 2025
September 28, 2025
2025
Showing 1 to 10 of 532 filings